Trial Profile
Does Administration of Recombinant Lecithin:Cholesterol Acyl Transferase (rLCAT) Lead To Reduction in Inflammatory Markers and Changes in Plaque Composition and Cell Cholesterol Content in Patients With Peripheral Vascular Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2018
Price :
$35
*
At a glance
- Drugs MEDI 6012 (Primary)
- Indications Atherosclerosis
- Focus Therapeutic Use
- Sponsors AlphaCore Pharma
- 27 Jul 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Dec 2012 New trial record